Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective

Journal of Medical Economics
Parthiv J MahadeviaLeonard B Weiner

Abstract

The cost-effectiveness of palivizumab has previously been reported among certain guideline-eligible, high-risk premature infants in Medicaid. Because guideline authorities base decisions on a national perspective, the economic model of palivizumab was adapted to include all infants, that is, public and privately insured patients (60% of palivizumab use is public, 40% is private). This study examined four groups of premature infants without chronic lung disease of prematurity or congenital heart disease: (1) <32 weeks gestational age (wGA) and ≤ 6 months chronologic age (CA); (2) 32-34 wGA, ≤ 3 months CA, with 2009 American Academy of Pediatrics (AAP) risk factors (RFs); (3) 32-35 wGA, ≤ 6 months CA, with 2006 AAP RFs; and (4) 32-35 wGA, ≤ 6 months CA, with ≤ 1 RF. An average estimate was used between public and private payors for (1) background rates of respiratory syncytial virus hospitalization (RSV-H), (2) direct medical costs associated with RSV-H, and (3) cost of palivizumab. Incremental cost-effectiveness ratios (ICERs) are reported in cost per quality-adjusted life-year (QALY) gained. Sensitivity analyses were performed. Palivizumab saved costs and improved QALYs among infants <32 wGA. Palivizumab was cost-effective in i...Continue Reading

References

Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Jan 1, 1996·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·J D Ferber
Oct 27, 1999·JAMA : the Journal of the American Medical Association·D K ShayL J Anderson
Oct 28, 1999·PharmacoEconomics·N MittmannB A Liu
Nov 15, 2003·The Journal of Pediatrics·Shelah Leader, Kimmie Kohlhase
Oct 5, 2006·Archives of Pediatrics & Adolescent Medicine·Nahed O ElhassanAndrew W Dick
Jun 26, 2007·The Journal of Pediatrics·Eric A F SimoesUNKNOWN Palivizumab Long-Term Respiratory Outcomes Study Group
Mar 28, 2008·Journal of Perinatology : Official Journal of the California Perinatal Association·M FrogelUNKNOWN Palivizumab Outcomes Registry Group
Jun 17, 2008·Medical Decision Making : an International Journal of the Society for Medical Decision Making·John S SampalisAndrea F Michaliszyn
Feb 7, 2009·The New England Journal of Medicine·Caroline Breese HallPeter Szilagyi
Oct 8, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·C Daniel MullinsJim Smeeding
Jan 16, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Hiroshi Mizuuchi
Mar 27, 2010·The Journal of Pediatrics·Cameron F GunvillePeter M Mourani
May 27, 2010·Pediatric Pulmonology·L Clark ParamorePedro A Piedra
Jul 16, 2010·Pediatric Pulmonology·Liisa PalmerParthiv J Mahadevia
Jul 27, 2010·Journal of Medical Economics·Kelly A SmartBosco A Paes
Jan 5, 2011·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Paul A ChecchiaRobert C Welliver
Aug 6, 2011·The Pediatric Infectious Disease Journal·Lauren J StockmanGayle Fischer-Langley
Mar 23, 2012·Journal of Medical Economics·Leonard B WeinerParthiv J Mahadevia
Jan 1, 1992·Journal of Research of the National Institute of Standards and Technology·Judith Newton

❮ Previous
Next ❯

Citations

Apr 9, 2014·Proceedings of the National Academy of Sciences of the United States of America·Andrew HiattLarry Zeitlin
Apr 26, 2014·PLoS Pathogens·Jia MengMartin L Moore
Aug 6, 2014·Proceedings of the National Academy of Sciences of the United States of America·Dan YanRichard Karl Plemper
Oct 13, 2015·Expert Review of Respiratory Medicine·Haben Y AbrahaBosco Paes
Nov 2, 2014·BMC Infectious Diseases·Javier Díez-DomingoPablo Lázaro
Nov 20, 2015·World Journal of Pediatrics : WJP·Bernhard ReschWerner Zenz
May 12, 2015·DNA and Cell Biology·Marco WeisshaarRichard K Plemper
Mar 26, 2013·Pulmonary Pharmacology & Therapeutics·William V La ViaGabriel J Robbie
Apr 26, 2016·Viruses·Philippe PlattetHector C Aguilar
Apr 7, 2015·Journal of the Pediatric Infectious Diseases Society·Christopher S Ambrose, Kimmie K McLaurin
Jun 13, 2018·Antimicrobial Agents and Chemotherapy·Jeong-Joong YoonRichard K Plemper
Mar 9, 2018·Open Forum Infectious Diseases·Natalia OlchanskiSean D Sullivan
Dec 18, 2018·Israel Journal of Health Policy Research·Gary M GinsbergYechiel Schlesinger
Sep 21, 2019·Current Drug Targets·Dhurvas Chandrasekaran DineshEvžen Bouřa
Jun 27, 2019·Allergologia et immunopathologia·C E Rodriguez-MartinezJ A Castro-Rodriguez
Mar 4, 2021·Infectious Diseases and Therapy·Michal Young, Lynn Smitherman
Jul 15, 2021·Human Vaccines & Immunotherapeutics·Kevin J Whaley, Larry Zeitlin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.